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ess under CC BY-NC-Abstract The secretion of melatonin (MT) is obviously different in the younger and the senior sectors of
the population, and the maximum plasma concentration of seniors is only half of that in the younger
population group. If exogenous MT can be supplied to senior citizens based on the secretion rate and
amount of endogenous MT in the younger population by a bio-mimetic drug delivery system (DDS), an
improved therapeutic effect and reduced side effects can be expected. Based upon this hypothesis, the
pharmacokinetic parameters of MT, namely, the absorption rate constant (ka), the elimination rate constant
(ke), and the ratio of absorption rate (F) to the apparent volume of distribution (V) were obtained by a
residual method depending on the plasma concentration curve of immediate release preparations in the
healthy younger population. The dose-division method was applied to calculate the cumulative release
proﬁles of MT achieved by oral administration of a controlled release drug delivery system (DDS) tol Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by
6
51 65169044.
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Bio-mimetic drug delivery systems 61generate plasma MT proﬁles similar to the physiological level-time proﬁles. The in vivo release of MT
deduced from the healthy younger population physiological MT proﬁles as the pharmacokinetic output of
the bio-mimetic DDS showed a two-phase proﬁle with two different zero order release rates, namely,
4.919 μg/h during 0–4 h (r¼0.9992), and 11.097 μg/h during 4–12 h (r¼0.9886), respectively. Since the
osmotic pump type of DDS generally exhibits a good correlation between in vivo and in vitro release
behaviors, an osmotic pump controlled delivery system was designed in combination with dry coating
technology targeting on the cumulative release characteristics to mimic the physiological MT proﬁles in
the healthy younger population. The high similarity between the experimental drug release proﬁles and the
theoretical proﬁles (similarity factor f2450) and the high correlation between the predicted plasma
concentration proﬁles and the theoretical plasma concentration proﬁles (r¼0.9366, 0.9163, 0.9264)
indicated that a prototype bio-mimetic drug delivery system of MT was established. The similarity factors
between the experimental drug release proﬁles and the theoretical release proﬁle were all larger than 50
both in periods of 0–4 h and 4–12 h, namely, 68.8 and 57.3 for the ﬁrst batch (Batch No. 20131031), 76.7
and 50.2 for the second batch (Batch No. 20131101), and 73.7 and 51.1 for the third batch (Batch No.
20131126), respectively. The correlation coefﬁcients between the predicted plasma concentration proﬁles
based on the release proﬁles of the bio-mimetic DDS and physiological proﬁles were 0.9366 (Batch No.
20131031), 0.9163 (Batch No. 20131101), 0.9264 (Batch No. 20131126), respectively. Since the
pharmacokinetic proﬁle of MT in any kind of animal differs markedly from that of human beings, it is
impossible to test the bio-mimetic DDS in animals directly. Therefore, the predicted pharmacokinetic
proﬁle based upon the in vitro release kinetics is an acceptable surrogate for the conventional animal test.
In this research, a bio-mimetic DDS for replacement of MT was designed with in silico evaluation.
& 2014 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Biological systems and physiological processes with amazing
properties and functions have been recognized and understood
over many years. Today, numerous engineers and scientists have
an appreciation for the sophistication of biological systems, and
they look into these for inspiration in their own research efforts1.
For example, by studying and imitating complex biological
system, researchers have used hormone replacement therapy
(HRT) to treat menopausal symptoms of senior women. A number
of senior women suffer from hot ﬂashes, anxiety, insomnia,
depression, genital tract inﬂammation by the decrease of estrogen
causing in menopause stage. HRT can improve and treat these
symptoms in menopause2. Another example is an intelligent drug
delivery system of insulin where insulin release has been regulated
by the different blood glucose levels, with the design aimed to
simulate the feedback mechanism of pancreas secreting insulin3.
However, these designs have not been developed according to the
secreting trend of endogenous substances, and bionic function has
only been achieved in part in these studies.
Currently, researchers have designed dosage forms according to
the circadian rhythm of endogenous substances or physiological
phenomena4. However, these designs represent a rough conven-
tional replacement, and fail to mimic the endogenous substance
fate in human bodies. These designs might cause plasma con-
centrations larger than desired maxima of endogenous substances
with the consequent side effects such as the case for corticoster-
oids, and an idealized treatment regime is not obtained.
In this study, the concept of bio-mimetic drug delivery system
(DDS) was termed as a well tailored system to administrate the
active physiological component at a predetermined rate proﬁle
based on optimized absorption and elimination of endogenous
substances. Firstly, the pharmacokinetic parameters of the endo-
genous substance administered were calculated by the residualmethod5 depending on the plasma concentration curve of immedi-
ate release preparations, and then the in vitro release proﬁle to
produce similar plasma level-time proﬁle as that by natural
secretion of endogenous substances were processed by the dose-
division method6. For the maintenance of physiological plasma
level-time proﬁles of different endogenous biochemicals, appro-
priate drug delivery systems should be designed.
Since the pharmacokinetic proﬁle of human natural biochem-
icals in any kind of test animal is dramatically different from that
of human beings, it is impossible to test the bio-mimetic DDS in
animals directly. Therefore, the predicted pharmacokinetic proﬁle
based upon the in vitro release kinetics is considered a suitable
surrogate for the conventional animal test. The plasma concentra-
tion of the active product of the bio-mimetic DDS can be predicted
in a reverse way to that of the dose-division method. A similarity
factor (f2)
7 can be used to calculate the similarity between drug
release curves of experimental results and that of theoretical
calculations, and the similarity between plasma concentration of
experimental results and that of predicted plasma levels. Thus it is
possible to estimate if the DDS is bio-mimetic, if the above two
similarities are determined.
The ﬂow chart (Fig. 1) details an appropriate and meaningful
method for designing a suitable formulation for the bio-mimetic
DDS by theoretical calculation and evaluation.
Melatonin (MT, N-acetyl-5-methoxyl primary amine) is an
indole amide neurohormone secreted by the pineal gland, which
exhibits distinct circadian rhythm of characteristics with extensive
physiological function and immunity8,9. MT can promote the
proliferation of B lymphocyte, inhibit the growth of tumor cells,
and activate endogenous antioxidant defense system and radical
scavenging system. MT can effectively prevent the occurrence of
cancer caused by oxidative DNA damage, and improve sleep
regulation to play a role of biological clock in human bodies.
However, ordinary dosage forms like immediate release tablets,
Figure 1 The ﬂow chart for the design of a bio-mimetic DDS for
melatonin.
Figure 2 The plasma drug concentration proﬁle of MT immediate
release preparations (the dosage was 0.5 mg)14.
Y. Li et al.62capsules, etc., have many shortcomings, e.g., unstable oral
absorption, fast distribution, rapid clearance (t1/2 is about 30–
50 min) and short residence time (1–3 h)10. Also, some sustained
or controlled drug release preparations are available. The efﬁcacy
and safety of these modiﬁed DDSs can be questioned, if they are
designed without plasma proﬁle similarity to that of the endogen-
ous rhythm of MT11.
An osmotic pump DDS has a number of unique advantages.
The DDS is not affected by medium environment such as pH,
enzymes, gastrointestinal peristalsis, and food factors for the
release of drug. Therefore, osmotic pump preparations have
been shown to be one of the best formulations to achieve good
correlation of in vivo and in vitro release behaviors. The
characteristics of zero order release can reduce trough-peak effect
and adverse reactions. Osmotic pump preparations can minimize
administration frequency and improve the medication compliance
and effectiveness for patients12,13. A biphasic release osmotic
pump DDS has been designed in this research to achieve a bio-
mimetic release proﬁle based on analysis of the secreting
characteristics of MT naturally occurring in human beings.2. Materials and methods
2.1. Reagents
MT (RS 12061050) was kindly gifted by Hainan Weikang
Pharmaceutical (Qianshan) Co., Ltd. (China). Polyoxyethylene
(WSR-N80) was supplied by Shanghai Colorcon Coating Tech-
nology Co., Ltd. (China). Lactose (Ludipresss LC) was produced
by Shanghai Yunhong Pharmaceutical Excipients Co., Ltd.
(China). Magnesium stearate (MS) was purchased from Anhui
Sunhere Pharmaceutical Excipients Co., Ltd. (China). Cellulose
acetate (CA) was obtained from Shanghai Chineway Pharmaceu-
tical Tech Co., Ltd. (China). PEG-4000 was supplied by Sichuan
Hanhua Pharmaceutical Excipients Co., Ltd. (China). Acetone was
of synthetic grade and purchased from Sinopharm Chemical
Reagent Co., Ltd. (China). Methanol and glacial acetic acid were
of HPLC grade produced by Merck Chemicals (Shanghai) Co.,
Ltd. (China). Ultra-pure water was prepared with a MilliQ-plus
system (Millipore, America).
2.2. Theoretical basis
No reports have been published to report on the various
pharmacokinetic parameters of human endogenous MT directly.
Thus, the in vivo pharmacokinetic parameters of exogenous MT
were calculated from the plasma pharmacokinetic curve of MTordinary immediate release formulations in human subjects14.
These pharmacokinetic parameters include the absorption rate
constant (ka), the elimination rate constant (ke), and the ratio of
absorption rate (F) to the apparent volume of distribution (V).
Based upon the pharmacokinetic parameters of MT, the controlled
release system can be designed to simulate the excretive level of
MT. According to in vitro release characteristics of controlled
release formulations, the cumulative release of each time (Ri), and
the release rate constant of each time period (k0) can be obtained
by dose-division method. The results show that the accumulative
release curves of physiological levels conform to two stages of
zero-order release.
2.2.1. Calculation of pharmacokinetic parameters for exogenous
MT
The residual method5 is a routine approach in pharmacokinetics to
obtain the ﬁrst order rate constants of absorption (ka) and
elimination rate constant (ke) as well as the ratio of absorption
rate to the apparent distribution volume (F/V). From the in vivo
plasma level proﬁle, ka, ke and F/V of exogenous MT were
obtained by the residual method based on the plasma concentration
curve of 0.5 mg MT immediate release formulations by oral
administration for all volunteers at 10:30 am14 (Fig. 2),
namely, ka was 1.36 h
1, ke was 1.21 h
1, and F/V was 3.07
106 mL1.
2.2.2. Calculation of MT in vivo release characteristics
The dose-division method15 uses zero-order release sub-doses to
approximate atypical release. Since the plasma levels of MT in
human populations are available, the theoretical in vivo release
proﬁles can be obtained through the dose-division method. Thus,
corresponding to the time [0, t1, t2,…, tn], in vivo plasma concentra-
tions are marked by [0, C1, C2,…, Cn]. The calculation process of
in vivo drug release kinetics in sustained or controlled release
formulations by the dose-division method is a process to calculate
the sub-doses with zero-order release rate ki at each time period.
The drug release of the ﬁrst time period can be divided into two
parts, one part is the amount absorbed by the body, and the other
part is that present at the absorption site ready to be absorbed This
portion is absorbed gradually when t4t1. During the release










Figure 3 Plasma concentration proﬁles of endogenous MT in
different populations16 (◆ younger women, ■ senior women, ▲
younger men, ● senior men).
Figure 4 Calculated in vivo drug release proﬁles of MT by dose-
division method in different populations (◆ younger women, ■ senior
women, ▲ younger men, ● senior men).
Bio-mimetic drug delivery systems 63Release rate (k1) is obtained as follows:
k1 ¼
CR;1keV
Fð1ðkae ket1 kee ka t1=kakeÞÞ
ð2Þ
The plasma concentrations contributed by the elimination phase
of the absorbed part on the subsequent time points (CE,i) are
CE;i ¼CR;1e kaðti  t1Þ ð3Þ
The concentrations contributed by the residues at the site to be




½e kaðti  t1Þ e keðti  t1Þ ð4Þ
According to Eqs. (3) and (4), plasma concentrations [C2,…, Cn]
deducted CE,i, CS,i, respectively. The plasma concentrations
[CR,2, …, CR,n] are obviously contributed by the other release rates
except k1. According to Eq. (1), k2 is calculated by CR,2. Similar
processes may help to get the drug release rate constants [k2,…, kn]
on subsequent periods of time. Thereafter, the cumulative in vivo
release proﬁle (Ri) is obtained as follows:
Ri ¼
∑ij ¼ 1kjðtj tj1Þ
∑nj ¼ 1kjðtj tj1Þ
 100% ð5Þ
It is obvious that plasma concentrations can be derived by
inverse direction, if the cumulative release (Ri) and release rate
constant (ki) are known.
2.2.3. Characteristics of MT bio-mimetic DDS
The pineal gland usually begins to secrete MT and other neuropep-
tides during the night. Ward16 pointed out that under normal
circumstances, a healthy younger population began to secrete MT
at about 18:00, and a peak concentration appeared at 02:00 in the
morning. Relative to this younger population, the MT peak concen-
tration in a senior population group was delayed for an hour, and the
maximum plasma concentration was only half of the younger group.
The change of plasma concentration in different gender and age of
populations also presented some differences. Speciﬁcally, the plasma
concentration of the younger group was signiﬁcantly higher than that
of the senior group, and the area under the curve (AUC) was
approximately two fold larger than that of the senior group (Fig. 3).
From the in vivo levels of endogenous MT in different populations
(Fig. 3), the secretion time of 18:00 was selected to be the initial time
to administer MT (0 h). Then, the cumulative release percentage at
each time point (0–12 h) was calculated by the dose-division method.
From this analysis, Fig. 4 shows the calculated in vivo drug release
proﬁles of MT for the four different populations given in Fig. 3.
From Fig. 4, the similarity factor between the calculated in vivo
drug release proﬁles of younger women and younger men was
73.1, and the similarity factor between the calculated in vivo drug
release proﬁles of senior women and senior men was 69.6. The
calculated in vivo drug release proﬁles for people of different
gender at the same age were similar.
The in vivo level of MT declines with age increasing, and
begins to decline after puberty. Thus the plasma concentration of
the senior population is lower than that of younger population
which may be due to the calciﬁcation of the pineal gland17.
However, the proﬁle of the cumulative release graph is almost the
same. In all further studies reported, the bio-mimetic DDS of MT
was designed by considering the in vivo level of MT for younger
women. The bio-mimetic DDS of MT applying to other popula-
tions can then be achieved by adjusting the dosage of the DDS.2.3. Design of MT bio-mimetic DDS
The calculated in vivo accumulative release curve of MT in
younger women (Fig. 4) was ﬁtted according to a number of
different drug release models18. As a consequence, the in vivo
release of MT in younger women is best ﬁtted by a model based
on two phases of zero order release. With the advantages of zero
order drug release, high correlation between in vitro–in vivo
release and being less affected by factors other than related to
the dosage form itself, osmotic pump preparations were selected to
be used as the bio-mimetic DDS.
2.4. Preparation of MT osmotic pump tablets
For senior people, a certain amount of MT can still be expected to
be secreted. Therefore, the expected in vivo level of MT should be
equal to the difference between the plasma concentration of MT
for younger people and that for the senior people. From the
positive correlation between the AUC and the drug dosage, the
dosage of the tablet was calculated to be 115 μg compared with
that of the immediate release preparations of MT (the dosage was
0.5 mg) reported with human plasma pharmacokinetics14.
For the preparation of the osmotic pump tablets, MT and other
excipients were all sieved through 100 mesh sieve and mixed
thoroughly. Then, a mixture containing 49 mg Ludipresss LC,
Figure 5 The two stage zero order release ﬁtting of the in vivo MT
level in younger women within 0–4 h and 4–12 h.
Y. Li et al.64115 μg MT and 1 mg MS for each inner core was weighed
5072 mg and tableted. The tablets were directly prepared with a
rotary tablet press (ZP-5, Tianjiu Machinery factory, Shanghai,
China) equipped with 5 mm D-tooling slightly concave-faced punch
tips. For the outer layer, a mixture of 10 mg WSR-N80, 39 mg
Ludipresss LC and 1 mg MS, half was put into the bottom of the
die ﬁtted with similar D-tooling but 6 mm diameter, the other half of
the outer materials was ﬁlled after the inner core being placed into
the center of the die. The outer layer materials were weighed
5072 mg, and the total weigh of each tablet was weighed
10075 mg, with content of MT as 11570.5 μg. In order to ensure
equal pressure, the thickness of inner core was kept at 170.07 mm,
and that of the whole each tablet was kept at 270.05 mm.
Tablet coating was carried out with a coating pan (BY-300A,
Shanghai Huanghai Medicine Checking Instrument Co., Ltd., Shang-
hai, China). CA in acetone containing PEG-4000 was used as the
coating solution (CA:PEG 4000¼5:1, w/w). The temperature of the
coating pan was 40 1C, and pan-rotating rate was 20 rpm. Weight
increase after coating was controlled to 5%. The coated tablets were
then dried to remove any residual solvent at 40 1C for 1 h. A laser
perforation in the coating tablets was made by a drilling laser (SD-
20W, Ceres Wuhan Photoelectric Technology Co., Ltd., Wuhan,
China), and the diameter of the pore was 0.6 mm.
2.5. In vitro release test
In vitro drug release test was conducted in a dissolution apparatus
(ZRS-8G, Tianjin Haiyida Tech Co., Ltd., Tianjin, China) with the
small cup paddle method according to Chinese Pharmacopeia
(2010, Department II, Appendix XC). The temperature was main-
tained at 3770.5 1C. Each osmotic pump tablet was entrapped into
a small cup and 100 mL of water was added. At 0.5, 1, 2, 4, 6, 8, 10
and 12 h, one milliliter of the dissolution solution was withdrawn
and the same volume of fresh medium was added. The solution was
immediately ﬁltered through a 0.22 μm membrane. Because of the
small dose of MT, the concentrations of MT in dissolution samples
were determined by LC/MS/MS analysis.
2.6. Evaluation of MT bio-mimetic DDS
The similarity factor (f 2)
7 was employed to evaluate the uniformity
of the experimental average release proﬁles for six osmotic pump
tablets compared with the ideal release proﬁle.
f 2 ¼ 50 lg f½1þ ð1=nÞ∑ðRtTtÞ20:5  100g ð6Þ
where f 2 is a logarithmic transformation of the sum-squared error of
differences between the experimental drug release Tt and the ideal
release Rt over all time points n. If the f 2 value is larger than 50, the
mean deviation of two proﬁles over all time points is less than 10%
and the proﬁles are believed to be similar. Then, it is close to the goal
of obtaining a bio-mimetic DDS.3. Results and discussion
3.1. Design of MT bio-mimetic DDS
The calculated in vivo cumulative release curve of MT in younger
women was ﬁtted to a two stage zero order release model. The
release was slower in 0–4 h, and faster in 4–12 h (Fig. 5). The
equations deﬁning these periods of release were y¼4.919xþ0.136(r¼0.9992) for 0–4 h and y¼11.09x28.14 (r¼0.9886) for
4–12 h, respectively.
The in vitro drug release can be seen as a “slow–fast” biphasic
proﬁle19, which exhibited two different release rates or two
different phases of release. Among the current sustained or
controlled release preparations, osmotic pump preparations gen-
erally provide a high correlation between in vivo and in vitro drug
release20, and the in vitro release characteristics of osmotic pump
preparations can better reﬂect the in vivo release behavior. Thus,
osmotic pump DDS is a good choice to achieve the goal of bio-
mimetic DDS.
The simulation of “slow–fast” biphasic delivery system in
Fig. 5 was carried out by the preparation of osmotic pump
preparations with “tablet-in-tablet” characteristics21. Osmotic
pump tablets were composed of three sections, the internal core
of tablets containing the drug and immediate-release excipients,
the middle section made up of hydrophilic polymer materials, and
the outer coating layer. This structure was designed to achieve the
“slow–fast” release characteristics required.3.2. LC/MS/MS analysis
The chromatographic separation was performed on an Agilent
1260 series HPLC system (Agilent Technologies Inc., China).
The separation was carried out on a Diamonsil C18 column
(150 mm 4.6 mm, 5 μm) with the column temperature of 40 1C.
The mobile phase consisted of methanol–0.1% formic acid
aqueous solution (60:40, v/v), at a ﬂow rate of 0.6 mL/min.
A sample solution of 1 μL was injected. The total run time for
each sample analysis was 5.5 min.
Mass spectrometric detection was performed using a G6460
tandem mass spectrometer (Agilent Technologies Inc., China)
equipped with an ESI. Nitrogen was used as nebulizer gas at 45 psi
and the drying gas under ﬂow of 5 L/min at 300 1C. The
instrument was operated with the capillary voltage at 3.5 kV.
Multiple reactions monitoring (MRM) was employed for data
acquisition. The optimized MRM fragmentation transition for MT
was m/z 233-m/z 174 with a fragment voltage of 95 V and
collision energy (CE) of 9 V.
The stock standard solution of MT (10 μg/mL) was prepared by
dissolving the drug in methanol and stored at 4 1C. Standard
solutions (5, 10, 20, 50, 100 and 200 ng/mL) were prepared
by dilution of the stock standard solution with pure water.
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concentration of MT in each assay over the concentration range of
5.0–200.0 ng/mL. The calibration curves were linear with a
correlation coefﬁcient Z0.9973 by least-squares linear regression
with the weighing factor of 1/x2. This validated linearity range
justiﬁed the concentration observed during real sample analysis.
The LLOQ (lower limit of quantiﬁcation) of the analysis was
0.1 ng/mL with the signal-to-noise ratio (S/N)Z10. The accuracy
and precision for MT determination were 102.3%–107.2% and
6.5%, respectively. Recovery of the analysis for the LQC
(8 ng/mL), MQC (80 ng/mL) and HQC (160 ng/mL) samples
was calculated, which were found to be 106.273.9%,
95.972.5% and 101.970.7%, respectively. For the experiment,
these data for the samples met the acceptance criteria at all
concentration tested.3.3. Evaluation of bio-mimetic DDS in comparison with the
theoretical physiological MT release
Three batches of osmotic pump tablets were prepared in this study.
The drug release curves are shown in Fig. 6. Depending on
Eq. (6), values of ƒ2 between the experimental and the theoretical
in vitro MT release proﬁle were all larger than 50 for periods of
0–4 h and 4–12 h. Namely, the ƒ2 values were 68.8 and 57.3 for
the ﬁrst batch (Batch No. 20131031), 76.7 and 50.2 for the second
batch (Batch No. 20131101), and 73.7 and 51.1 for the third batch
(Batch No. 20131126), respectively. In addition, the similarity
factors were also larger than 50 over the total drug release periodFigure 6 The experimental in vitro drug release proﬁle of MT osmotic
pump tablets and the calculated in vitro release of physiological MT
(◆ 20131031, ■ 20131101, ▲ 20131126, ● physiological MT).
Figure 7 Calculated in vivo plasma concentration curves of MT for thr
division method (◆ 20131031, ■ 20131101, ▲ 20131126, ● physiologicalof 0–12 h, namely, 61.5, 53.4 and 55.6, respectively. These results
showed that the characteristics of the experimental in vitro release
of MT were similar to that of the theoretical calculation and that
the bio-mimetic simulation of the MT in vitro release has been
achieved by the prepared osmotic pump tablets.3.4. Evaluation of bio-mimetic DDS by the expected in vivo MT
levels
Due to differences of absorption and elimination process between
animals and human, it was unable to evaluate that whether in vivo
pharmacokinetic behavior of MT osmotic pump tablets accorded
with bionic requirements from experiments in animals. In this
research, the expected in vivo plasma concentrations of MT were
inversely derived by the experimental release results. Then the
similarity of data can be obtained by comparing the experimental
in vivo level of MT with that of the physiological characteristics.
According to the similarity results, the in vivo bio-mimetic result
of the DDS can be evaluated.
On the basis of the dose-division method, in vivo plasma
concentrations of exogenous MT were calculated based on the
release rate of three batches of MT osmotic pump tablets. Fig. 2
showed that the senior population still secreted a certain amount of
MT, and the maximum plasma concentration was half that of a
younger population. Thus, the ﬁnal plasma concentration of MT in
the body should be the sum of the concentration of endogenous
and exogenous MT. The plasma concentration of conventional MT
sustained release tablets22 with a dose of 2 mg had been predicted
by the way. If all the MT dosage forms were administered at 18:00
p.m., the predicted plasma proﬁles of MT for the osmotic pump
tablets and the conventional sustained release tablets at different
times (Fig. 7).
The correlation analysis between the predicted plasma concen-
tration curves for MT osmotic pump tablets in the senior
population and physiological MT plasma concentration was
carried out. Results indicated that osmotic pump tablets were
similar to the physiological MT plasma proﬁle, namely, the
correlation coefﬁcients (r) were 0.9366 (Batch No. 20131031),
0.9163 (Batch No. 20131101), 0.9264 (Batch No. 20131126)
respectively (Fig. 7, left), while the predicted plasma concentration
curve for MT conventional sustained release tablets was not
similar to that of MT physiological proﬁle (r¼0.1218) (Fig. 7,
right). The results suggested that the conventional controlled/
sustained release systems were not bio-mimetic and the design in
this research was achieved at the goal of a bio-mimetic DDS.ee batches osmotic pump tablets, physiological release and by dose-
release, ◇ release of MT conventional sustained release tablets).
Y. Li et al.664. Conclusions
The secretion of endogenous MT has a time rhythm. However, the
dose levels of the conventional oral pharmaceutical preparations are
much higher than the physiological ones. In addition, the time rhythm
of endogenous MT was not considered in the design of ordinary
preparations, which may cause side effects following treatment, and be
unable to achieve the best therapeutic effect. In this study, the novel
design methodology of bio-mimetic DDS was investigated. Due to the
differences of absorption and elimination process between animals and
human beings, it is not possible to test whether the goal of bio-
mimetic DDS is achieved using animal experimentation. Therefore,
prediction of the plasma level based upon the release of a bio-mimetic
DDS is of interest to enable the delivery of appropriate amounts at the
correct rates of the endogenous material for replacement therapy.
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